Merus N.V. (MRUS) Analysts See $-0.88 EPS

June 13, 2018 - By Tina Thibodeau

Analysts expect Merus N.V. (NASDAQ:MRUS) to report $-0.88 EPS on July, 10.They anticipate $0.35 EPS change or 28.46 % from last quarter’s $-1.23 EPS. After having $-0.86 EPS previously, Merus N.V.’s analysts see 2.33 % EPS growth. The stock increased 0.88% or $0.17 during the last trading session, reaching $19.59. About 12,281 shares traded. Merus N.V. (NASDAQ:MRUS) has declined 2.28% since June 13, 2017 and is downtrending. It has underperformed by 14.85% the S&P500.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company has market cap of $443.22 million. The Company’s lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. It currently has negative earnings. The firm also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.

More important recent Merus N.V. (NASDAQ:MRUS) news were published by: Nasdaq.com which released: “Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors” on May 24, 2018, also Globenewswire.com published article titled: “Merus to Present at the Jefferies 2018 Healthcare Conference”, Globenewswire.com published: “Analysis: Positioning to Benefit within China Biologic Products, Merus NV, Adient, G1 Therapeutics, Westport Fuel, and …” on June 06, 2018. More interesting news about Merus N.V. (NASDAQ:MRUS) was released by: Streetinsider.com and their article: “Merus NV (MRUS) Says Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer …” with publication date: May 15, 2018.

Merus N.V. (NASDAQ:MRUS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: